Literature DB >> 17170743

Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma.

Mattias Berglund1, Gunilla Enblad, Ulf Thunberg, Rose-Marie Amini, Christer Sundström, Göran Roos, Martin Erlanson, Richard Rosenquist, Catharina Larsson, Svetlana Lagercrantz.   

Abstract

Follicular lymphoma is commonly transformed to a more aggressive diffuse large B-cell lymphoma (DLBCL). In order to provide molecular characterization of this histological and clinical transformation, comparative genomic hybridization was applied to 23 follicular lymphoma and 35 transformed DLBCL tumors from a total of 30 patients. The results were also compared with our published findings in de novo DLBCL. Copy number changes were detected in 70% of follicular lymphoma and in 97% of transformed DLBCL. In follicular lymphoma, the most common alterations were +18q21 (33%), +Xq25-26 (28%), +1q31-32 (23%), and -17p (23%), whereas transformed DLBCL most frequently exhibited +Xq25-26 (36%), +12q15 (29%), +7pter-q22 (25%), +8q21 (21%), and -6q16-21(25%). Transformed DLBCL showed significantly more alterations as compared to follicular lymphoma (P=0.0001), and the alterations -6q16-21 and +7pter-q22 were only found in transformed DLBCL but not in follicular lymphoma (P=0.02). Alterations involving +13q22 were significantly less frequent, whereas -4q13-21 was more common in transformed as compared to de novo DLBCL (P=0.01 and P=0.02, respectively). Clinical progression from follicular lymphoma to transformed DLBCL is on the genetic level associated with acquisition of increasing number of genomic copy number changes, with non-random involvement of specific target regions. The findings support diverse genetic background between transformed and de novo DLBCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17170743     DOI: 10.1038/modpathol.3800708

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  3 in total

1.  Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression.

Authors:  Brygida Bisikirska; Mukesh Bansal; Yao Shen; Julie Teruya-Feldstein; Raju Chaganti; Andrea Califano
Journal:  Cancer Res       Date:  2015-11-20       Impact factor: 12.701

2.  Apoptosis inhibition or inflammation: the role of NAIP protein expression in Hodgkin and non-Hodgkin lymphomas compared to non-neoplastic lymph node.

Authors:  Safoura Mazrouei; Amin Ziaei; Amir Pouya Tanhaee; Kianoosh Keyhanian; Mahdad Esmaeili; Azar Baradaran; Mansoor Salehi
Journal:  J Inflamm (Lond)       Date:  2012-02-23       Impact factor: 4.981

3.  Amplification of 2p as a genomic marker for transformation in lymphoma.

Authors:  Anna Kwiecinska; Koichi Ichimura; Mattias Berglund; Andrii Dinets; Luqman Sulaiman; V Peter Collins; Catharina Larsson; Anna Porwit; Svetlana Bajalica Lagercrantz
Journal:  Genes Chromosomes Cancer       Date:  2014-05-15       Impact factor: 5.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.